Even in the case of uncomplicated infections, the body prepares itself early on for the possibility of a more severe course.

The real-world safety profile of tisagenlecleucel appears to be more favourable than that reported in the JULIET study, which led to its FDA approval.

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...